Showing results (71-80 of 715) with videos related to
Sort By:
Pageof 72
Nature Reviews. Drug Discovery|September 15, 2007
Flying under the radar: the new wave of BCR-ABL inhibitorsAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge CortesClinical Advances in Hematology & Oncology : H&O|November 29, 2012
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemiaJorge Cortes, Jerald Radich, Michael J MauroBest Practice & Research. Clinical Haematology|March 6, 2003
New agents in the treatment of acute lymphocytic leukaemiaDeborah A Thomas, Jorge Cortes, Hagop M KantarjianExpert Review of Anticancer Therapy|July 11, 2009
Azacitidine for the treatment of myelodysplastic syndromeVince D Cataldo, Jorge Cortes, Alfonso Quintás-CardamaExpert Opinion on Pharmacotherapy|November 16, 2010
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemiaAmber Fullmer, Hagop Kantarjian, Jorge Cortes, et al.Cancer|February 15, 2011
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.Leukemia & Lymphoma|February 9, 2011
New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemiaAmber Fullmer, Hagop Kantarjian, Jorge Cortes, et al.Cancer Medicine|January 2, 2024
County-level colorectal cancer screening rates on colorectal cancer survival in the state of Georgia: Does county-level rurality matter?Meng-Han Tsai, Steven S Coughlin, Jorge CortesJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2011
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemiaJorge Cortes, Andreas Hochhaus, Timothy Hughes, et al.Drug Design, Development and Therapy|November 19, 2009
Development and targeted use of nilotinib in chronic myeloid leukemiaCarmen Fava, Hagop Kantarjian, Jorge Cortes, et al.Pageof 72